Abstract: A liver-targeted drug and therapeutic use thereof for diseases requiring drug action in the liver are disclosed. A method in which a substance having activity with respect to glucagon is used so as to induce delivery of the liver-targeted drug to liver tissues or an increase in distribution of the drug in liver tissues after in vivo administration.

Abstract: A sustained release preparation of a human growth hormone conjugate is disclosed. The sustained release preparation contains a sustained release human growth hormone (hGH) conjugate resulting from conjugation between an immunoglobulin Fc region and a human growth hormone (hGH) as an active peptide; a buffer solution; a nonionic surfactant; and a sugar alcohol. A freeze dried preparation and a liquid preparation including the sustained release human growth hormone conjugate, a production method for the freeze dried preparation, a method of reconstituting the freeze dried preparation, and a kit containing the freeze dried preparation and a reconstituting solution are also disclosed.

Abstract: A liver-targeted drug and therapeutic use thereof for diseases requiring drug action in the liver are disclosed. Additionally, a method in which a substance having activity on glucagon is used so as to induce delivery of the drug to the liver tissue or an increase in distribution of the drug in the liver tissue after in vivo administration.

Abstract: The present invention relates to a container, which accommodates a drug and is sealed, includes a container stopper part including at least one filling groove formed in order to inject a drug, and a container body including an opening into which the container stopper part is inserted and which is sealed, wherein the filling groove is formed in an outer wall surface of the container stopper part in a longitudinal direction in which the container stopper part is inserted thereinto and forms a passage which is formed between the outer wall surface of the container stopper part and an inner wall surface of the container body and through which the drug is injectable.

Abstract: Provided are crystalline forms of acid addition salts of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)furo[3,2-d]pyrimidin-4-yloxy)phenyl)acrylamide, and a pharmaceutical composition including the same. The crystalline forms may be easily used in preparing the pharmaceutical composition including the same as an active ingredient.

Abstract: A semaglutide soluble microneedle composition and a preparation method therefor are disclosed. The soluble microneedle composition comprises a needle material and a base material. The needle material comprises semaglutide and hyaluronidase, and a mass ratio of semaglutide to hyaluronidase is (0.05-172):1. The semaglutide and the hyaluronidase are combined to prepare the soluble microneedle composition, so that the semaglutide can be better promoted to diffuse into the systemic circulation. Compared with a semaglutide oral tablet, the soluble microneedle composition has the advantages that the blood sugar regulating effect is improved by nearly 40 times, the bioavailability of semaglutide is improved, and the dosage and the cost of the hypoglycemic drug are reduced. Moreover, the soluble microneedle technology causes no pain during use and reduces the discomforts of users.

Abstract: The present invention relates to a method for preparing a triazolopyrimidinone derivative exhibiting tankyrase inhibitory activity and an intermediate thereof. The preparation method of the present invention can improve reaction efficiency through the development of efficient processes and can prepare a triazolopyrimidinone derivative compound with high purity and high yield, and thus is economical and suitable for mass production.

Abstract: A method for preparing an oral composite tablet containing a proton pump inhibitor and an antacid and an oral composite tablet prepared by the method are disclosed. The method prepare an oral composite tablet with excellent appearance stability and high productivity. The proton pump inhibitor includes esomeprazole, omeprazole, lansoprazole, rabeprazole, pantoprazole, or combinations thereof.

Abstract: The present invention provides a novel method for preparing high-purity gadobutrol or hydrates thereof. The preparation method of the present invention can have an advantage of simplifying a process by forming a gadolinium complex in-situ without purification of a butrol intermediate and omitting a resin purification process unlike a conventional method for synthesizing gadobutrol. In addition, the preparation method of the present invention can be used to produce high-purity gadobutrol or hydrates thereof at a high yield only through the simple process as above, and thus can be useful in mass production.

Abstract: The invention discloses a genetically engineered bacterium in which the gene encoding adenine deaminase on the genome of the bacterium is knocked out or/and the gene encoding the enzyme in the NAD+ anabolic pathway is integrated on the genome of the bacterium. The invention also discloses a construction method of the above-mentioned genetically engineered bacteria. The gene encoding adenine deaminase on the genome of the host strain is knocked out to obtain a strain with high NAD+ yield. Or the expression cassettes of the gene encoding the enzyme in the NAD+ synthesis pathway are constructed separately, and then the enzyme encoding The gene expression cassette is integrated into the genome of the host strain whose gene encoding adenine deaminase is knocked out to construct a strain with high NAD+ production. The application of the above genetically engineered bacteria is disclosed. A method of producing NAD+ is disclosed.

Abstract: The present invention relates to the technical field of medicine, and in particular, relates to a composition of vancomycin aqueous solution. The pharmaceutical composition contains vancomycin or a pharmaceutically acceptable salt thereof, N-methylalanine, and water. The stability of vancomycin in the state of an aqueous solution can be improved by using N-methylalanine.

Abstract: Polyethylene glycol derivatives of the following formula I and uses thereof are disclosed. A method for manufacturing the polyethylene glycol derivatives is also disclosed.

Abstract: The present invention provides a compound of chemical formula 1, a compound of chemical formula 3, compound [212], compound [224], or compound [228], a pharmaceutically acceptable salt thereof, a stereoisomer thereof, a hydrate thereof, or a solvate thereof, and a pharmaceutical composition comprising same. The pharmaceutical composition has excellent antiviral efficacy, thereby having a preventive or treatment effect on viral infectious disease such as SARS-COV-2, and exhibits an inhibitory effect on IL-5 expression and thus has a preventive or treatment effect on respiratory disease or allergic disease.

Abstract: A composition, suitable for an orally administered formulation, contains a GLP-1 analogue and, particularly, a hydrophobic ion-pair of a GLP-1 analogue and an oil phase. The pharmaceutical composition for oral administration forms an emulsion surrounding the hydrophobic ion-pair when exposed to a water phase, so as to be stably absorbed without being decomposed by digestive enzymes, and thus provides an effective and prolonged pharmacological effect. Methods for producing the composition for oral administration are also disclosed.

Abstract: The claimed invention relates to treatment of virus-related neurological symptoms, particularly methods for treating such symptoms by administering a complement inhibitor. The types of virus-related neurological symptoms that can be treated according to the invention include extreme fatigue, sensory loss such as loss of taste, cognitive changes, seizures, tremor, and stroke, and can be linked to infection by a coronavirus such as SARS-CoV-2. The invention includes administering complement inhibitor, which can be recombinant or purified C1 inhibitor.

Abstract: A surgical instrument for repairing a cartilage tear, of the present invention, can simply and safely fix a first fixing piece (501) and a second fixing piece (502) to a torn cartilage through a very simple method for sequentially discharging the first fixing piece (501) and the second fixing piece (502) provided to be connected to suture threads (10) through a needle (411) at the tip of a push rod guide (410) while selectively moving a push rod (200) a predetermined width forward in multiple stages by means of an operation of pressing and lowering a push button (300), which is inserted into a button coupling hole (120) of an instrument body (100) so as to receive the elastic repulsive force of a spring (310), or releasing and lifting the pressed button.

Abstract: The present invention provides a novel thiazole derivative or a pharmaceutically acceptable salt thereof, and a method for preparing the same. The thiazole derivative or pharmaceutically acceptable salt thereof according to the present invention has selective inhibitory activity against cyclin-dependent kinase (CDK) and thus can be used as a preventive or therapeutic agent for various diseases associated with CDK.

Abstract: An oral dosage form in a form of a bi-layer complex tablet is disclosed. The bi-layer oral complex tablet contains colloidal silicon dioxide in an amount of 0.5 to 2% by weight based on a total weight of the first layer. A method for manufacturing the bi-layer oral complex tablet dosage form is also disclosed.

Abstract: The present invention relates to a method for preparing a pyrrolopyridine derivative compound exhibiting antiviral activity, and a novel intermediate used therein. The preparation method of the present invention enables reaction steps to be reduced through effective process development and a high purity pyrrolopyridine derivative compound to be prepared in a high yield, and thus enables production costs to be remarkably reduced so as to be economical and to be suitable for mass production.

Abstract: Provided are a crosslinked hyaluronic acid product in the form of powder and a method of preparing the same, and a crosslinked hyaluronic acid hydrogel prepared using the crosslinked hyaluronic acid product in the form of powder, and a method of preparing the same. The crosslinked hyaluronic acid hydrogel according to the present disclosure exhibits excellent rheological properties, and mass production thereof is easy and quality uniformity thereof is excellent.